Increased Expression of Functional Fas-Ligand in Activated T Cells from Patients with Systemic Lupus Erythematosus

References

• Cohen J. J. Apoptosis. Immunol Today 1993; 14: 126–130
   PubMedGoogle Scholar
• Cohen J. J. Programmed cell death and apoptosis in lymphocyte development and function. Chest 1993; 103: 99S–101S
   PubMed Web of Science ®Google Scholar
• Krammer P. H., Behrmann I., Daniel P., Dhein J., Debatin K. M. Regulation of apoptosis in the immune system. Curr Opin Immunol 1994; 6: 279–289
   PubMed Web of Science ®Google Scholar
• Green D. R., Scott D. W. Activation-induced apoptosis in lymphocytes. Curr Opin Immunol 1994; 6: 476–487
   PubMed Web of Science ®Google Scholar
• Kabelitz D., Pohl T., Pechhold K. Activation-induced cell death (apoptosis) of mature peripheral T lymphocytes. Immunol Today 1993; 14: 338–339
   PubMedGoogle Scholar
• Wesselborg S., Janssen O., Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol. 1993; 150: 4338–4345
   PubMed Web of Science ®Google Scholar
• Radvanyi L. G., Mills G. B., Miller R. G. Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death. J. Immunol. 1993; 150: 5704–5715
   PubMed Web of Science ®Google Scholar
• Klas C., Debatin K. M., Jonker R. R., Krammer P. H. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 1993; 5: 625–630
   PubMed Web of Science ®Google Scholar
• Alderson M. R., Tough T. W., Davis-Smith T., Braddy S., Falk B., Schooley K. A., et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 1995; 181: 71–77
   PubMed Web of Science ®Google Scholar
• Ju S. T., Panka D. J., Cui H., Ettinger R., el-Khatib M., Sherr D. H., et al. Fas (CD95)/FasL interactions required for programmed cell death after T cell activation [see comments]. Nature 1995; 373: 444–448
   PubMed Web of Science ®Google Scholar
• Dhein J., Walczak H., Baeumler C., Debatin K. M., Krammer P. H. Autocrine T cell suicide mediated by APO-1/(Fas/CD95). Nature 1995; 373: 438–441
   PubMed Web of Science ®Google Scholar
• Brunner T., Mogil R. J., LaFace D., Yoo N. J., Mah-Boubi A., Echeverri F. S., et al. Cell-autonomous Fas(CD95)/Fas ligand interaction mediates activation-induced apoptosis in T cell hybridomas. Nature 1995; 373: 441–444
   PubMed Web of Science ®Google Scholar
• Wu J., Zhou T., He J., Mountz J. D. Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J. Exp. Med. 1993; 178: 461–468
   PubMed Web of Science ®Google Scholar
• Ramsdell F., Seaman M. S., Miller R. E., Tough T. W., Alderson M. R., Lynch D. H. gld/gld mice are unable to express a functional ligand for Fas. Eur. J. Immunol. 1994; 24: 928–933
   PubMed Web of Science ®Google Scholar
• Ettinger R., Wang J. K., Bossu P., Pappas K., Sidman C. L., Abbas A. K., Marshak-Rothstein A. Functional distinctions between MRL-1 pr and MRL-gld lymphocytes. Normal cells reverse the gld but not the 1pr immunoregulatory defect. J. Immunol. 1994; 152: 1557–1568
   PubMed Web of Science ®Google Scholar
• Tsokos G. C. Overview of cellular immune function in systemic lupus erythematosus. Systemic Lupus Erythematosus, R. G. LaHita. Churchill Livingstone, New York 1994; 13–48
   Google Scholar
• Emlen W., Niebur J., Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 1994; 152: 3685–3692
   PubMed Web of Science ®Google Scholar
• Richardson B. C, Yung R. L., Johnson K. J., Rowse P. E., Lalwani N. D. Monocyte apoptosis in patients with active lupus. Arthritis Rheum 1996; 39: 1432–1434
   PubMedGoogle Scholar
• Aringer M., Wintersberger W., Steiner C. W., Kiener H., Presterl E., Jaeger U., Smolen J. S., Graninger W. B. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1423–1430
   PubMed Web of Science ®Google Scholar
• Cheng J., Zhou T., Liu C., Shapiro J. P., Brauer M. J., Kiefer M. C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759–1762
   PubMed Web of Science ®Google Scholar
• Mysler E., Bini P., Drappa J., Ramos P., Friedman S. M., Krammer P. H., Elkon K. B. The apoptosis-1/Fas protein in human systemic lupus erythematosus. J. Clin. Invest. 1994; 93: 1029–1034
   PubMed Web of Science ®Google Scholar
• Tan E. M., Cohen A. S., Fries K. F., Masi A. T., McShane D. J., Rothfield N. F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271
   PubMed Web of Science ®Google Scholar
• Bombardier C., Gladman D. D., Urowitz M. B., Caron D., Chang C. H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35: 630–640
   PubMed Web of Science ®Google Scholar
• Kovacs B., Tsokos G. C. Cross-linking of the Fas/APO-1 antigen suppresses the CD3-mediated signal transduction events in human T lymphocytes. J Immunol 1995; 155: 5543–5549
   PubMed Web of Science ®Google Scholar
• Yonehara S., Nishimura Y., Kishil S., Yonehara M., Takazawa K., Tamatani T., Ishii A. Involvement of apoptosis antigen Fas in clonal deletion of human thymocytes. Int. Immunol. 1994; 6: 1849–1856
   PubMed Web of Science ®Google Scholar
• Nagata S., SudaFas T. Fas ligand: lpr and gld mutations. Immunol Today, 16: 39–43
   PubMedGoogle Scholar
• Ramsdell F., Seaman M S, Miller R. E., Tough T. W., Alderson M. R., Lynch D. H. gld/gld mice are unable to express a functional ligand for Fas. Eur. J. Immunol 1994; 24: 928–933
   PubMed Web of Science ®Google Scholar
• Takahashi T., Tanaka M., Brannan C. I., Jenkins N. A., Copeland N. G., Suda T., Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969–976
   PubMed Web of Science ®Google Scholar
• Mountz J. D., Wu J., Cheng J., Zhou T. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 1994; 37: 1415–1420
   PubMed Web of Science ®Google Scholar
• Drappa J., Vaishnaw A. K., Sullivan K. E., Chu J. L., Elkon K. B. Thirty year follow up of humans with Fas mutations. Arthritis Rheum 1996; 39: S217, (Abstract)
   Google Scholar
• Amasaki Y., Kobayashi S., Takeda T., Ogura N., Jodo S., Nakabayashi T., et al. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Clin Exp Immunol 1995; 99: 245–250
   PubMed Web of Science ®Google Scholar
• Mohan C., Adams S., Stanik V., Datta S. K. Nucleosome: a major immunogen for pathogenic autoanti-body-inducing T cells of lupus. J. Exp. Med. 1993; 177: 1367–1381
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen L., Rosen A., Petri M., Schliessel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: Implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc. Natl. Acad. Set. USA 1996; 93: 1624–1629
   PubMed Web of Science ®Google Scholar